Cargando…

Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT

To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered. Haematological, liver and renal toxicities were collected and graded according to CTCAE v5. Patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scalorbi, Federica, Argiroffi, Giovanni, Baccini, Michela, Gherardini, Luca, Fuoco, Valentina, Prinzi, Natalie, Pusceddu, Sara, Garanzini, Enrico Matteo, Centonze, Giovanni, Kirienko, Margarita, Seregni, Ettore, Milione, Massimo, Maccauro, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484673/ https://www.ncbi.nlm.nih.gov/pubmed/34593940 http://dx.doi.org/10.1038/s41598-021-99048-8

Ejemplares similares

Author Correction: Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
por: Scalorbi, Federica, et al.
Publicado: (2023)

Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups
por: Centonze, Giovanni, et al.
Publicado: (2020)

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
por: Prisciandaro, Michele, et al.
Publicado: (2022)

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
por: Centonze, Giovanni, et al.
Publicado: (2021)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence
por: Pusceddu, Sara, et al.
Publicado: (2020)

Radioembolization of Hepatocellular Carcinoma with (90)Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose–Response Analysis with Two Radiological Methods
por: Romanò, Chiara, et al.
Publicado: (2022)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
por: Harris, Philip E., et al.
Publicado: (2022)

Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
por: Pusceddu, Sara, et al.
Publicado: (2021)

Hybrid mesons on the lattice with FLIC fermions
por: Hedditch, J N, et al.
Publicado: (2003)

CT, [(18)F]FDG-PET/CT and clinical findings before and during early Covid-19 onset in a patient affected by vascular tumour
por: Kirienko, Margarita, et al.
Publicado: (2020)

Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2020)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
por: Michetti, Caterina, et al.
Publicado: (2017)

Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report
por: Valente, Monica, et al.
Publicado: (2010)

The FTK to Level-2 Interface Card (FLIC)
por: Anderson, John Thomas, et al.
Publicado: (2015)

The FTK to Level-2 Interface Card (FLIC)
por: Wang, R., et al.
Publicado: (2015)

Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise
por: Bartolomei, Mirco, et al.
Publicado: (2022)

Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study
por: Massironi, Sara, et al.
Publicado: (2022)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
por: Corti, Francesca, et al.
Publicado: (2023)

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

Immune response to recombinant Burkholderia pseudomallei FliC
por: Koosakulnirand, Sirikamon, et al.
Publicado: (2018)

Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
por: Roll, Wolfgang, et al.
Publicado: (2021)

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE
por: Pettersson, Olof Joakim, et al.
Publicado: (2021)

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms
por: Milione, Massimo, et al.
Publicado: (2019)

Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2022)

Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
por: Ricci, Angela Dalia, et al.
Publicado: (2022)

Cloning of fimH and fliC and expression of the fusion protein FimH/FliC from Uropathogenic Escherichia coli (UPEC) isolated in Iran
por: Asadi, Karam MR, et al.
Publicado: (2012)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

FLIC: High-Throughput, Continuous Analysis of Feeding Behaviors in Drosophila
por: Ro, Jennifer, et al.
Publicado: (2014)

Functional study and pathogenicity classification of PRRT2 missense variants in PRRT2‐related disorders
por: Zhao, Shao‐Yun, et al.
Publicado: (2019)

Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications
por: Simbolo, Michele, et al.
Publicado: (2022)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up
por: Vernieri, Claudio, et al.
Publicado: (2016)

Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum
por: Milione, Massimo, et al.
Publicado: (2012)

Validation of the English and Chinese versions of the Quick-FLIC quality of life questionnaire
por: Cheung, Y-B, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_jdhk0fjjsbsgn3vt9n7a20h9i0